

## Change to Director Seeking Re-election at AGM

**Melbourne, Australia, 21 October 2019:** [Sienna Cancer Diagnostics Ltd \(ASX: SDX\)](#) ("Sienna" or "the Company"), wishes to advise shareholders that due to the recent appointment of Mr Carl Stubbings to the role of Chief Executive Officer and Managing Director, the resolution seeking shareholder approval for his re-election included in the notice of meeting for the Company's upcoming Annual General Meeting (AGM) is no longer valid.

In accordance with Sienna's constitution there must be an election of director/s at each AGM, therefore Dr David Earp will replace Mr Stubbings as the director seeking re-election at the 2019 AGM. Resolution 2 now reads:

### **Resolution 2: Election of Dr David J. Earp**

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:

*"That pursuant to section 13.3 of the Company's Constitution and for all other purposes, Dr David J. Earp retires and offers himself for re-election as an Independent Non-executive Director of the Company."*

An updated notice of meeting and proxy form will follow this announcement. We ask shareholders to use this proxy form in place of the one recently sent to shareholders.

Shareholders who elected to receive a hard copy of the notice of meeting and proxy form can request replacement copies of the amended notice and form by contacting the Company using the details below.

Shareholders who have already returned a completed proxy form to the company's share registrar, Link Market Services, and wish to lodge a vote in relation to the amended resolution may complete and return a copy of the updated proxy form.

Shareholders who have already lodged their votes online, and wish to vote on the amended resolution, can do so using the link in a new email which will be sent to you following the lodgement of this notice.

Sienna will ensure that only one vote per share per resolution shall be counted when tallying the votes for each resolution.

ENDS

**For further information, please contact:**

Tony Di Pietro, CFO & Company Secretary  
Sienna Cancer Diagnostics  
[tdipietro@siennadiagnostics.com.au](mailto:tdipietro@siennadiagnostics.com.au)  
+61 3 8288 2141

Kyahn Williamson  
WE Buchan  
[sienna@we-buchan.com](mailto:sienna@we-buchan.com)  
+61 3 8866 1200



## About Sienna Cancer Diagnostics

Sienna Cancer Diagnostics Ltd. (“the Company”, or “Sienna”) is an Australian medical technology company with operations in the United States and Australia, and distributors for its products in the United States, Europe, Asia and Latin America.

Sienna’s vision is to become a hub for the development and commercialisation of *in-vitro* diagnostic (IVD) tests for the global pathology market. Our mission is to create a portfolio of products to bring to market much needed cancer diagnostic solutions, which will in turn generate additional revenue and long-term growth for Sienna’s shareholders.

Sienna’s strengths lie in the identification, development and commercialisation of novel IVD technologies that satisfy an unmet clinical / market need. Our first product is an antibody-based IVD test to detect the biomarker “hTERT”. Sienna has taken the hTERT test from research, through development and manufacturing, to product registration and sales through a growing network of distribution partners.

The Company intends to fill an important gap in the Australian MedTech ecosystem, by providing a capable, efficient and effective development, manufacturing and commercial launch pathway for IVD technologies sourced from leading universities and research institutions.

As part of this technology expansion strategy, Sienna recently acquired a unique technology for the capture and isolation of target biomarkers in liquid biopsy samples. The sample preparation technology, known as SIEN-NET™, can more accurately and rapidly prepare samples for the liquid biopsy testing of a range of clinically useful biomarkers, including exosomes, lipids, proteins, and other molecular targets of interest.

We are focussed on growing revenues from the hTERT test, increasing market access through new distribution partnerships, commercialisation of the SIEN-NET™ product line, and expanding our product offerings with the addition of new technologies.

